Investors seeking direct access to emerging life sciences companies will have an opportunity on September 17, 2026, when the Life Sciences Virtual Investor Forum convenes online. Hosted by Virtual Investor Conferences and marketed by B2i Digital, Inc., the event will feature 30-minute live presentations followed by audience Q&A, with replays available on demand. The forum’s lineup spans a diverse set of therapeutic areas and technologies, from photothermal cancer therapy to cannabinoid-based formulations and precision drug delivery.
The presenting companies, as of September 11, 2026, include Sona Nanotech Inc., Raphael Pharmaceutical, Amplia Therapeutics Ltd., Adaptin Bio, Inc., Acurx Pharmaceuticals, Inc., CytoDyn Inc., and 4DMedical Ltd. Their work covers oncology, fibrosis, drug delivery, antibiotics, cannabinoid therapeutics, and respiratory imaging. For investors, the event offers a chance to hear directly from management teams about pipeline progress and strategic priorities, which can be more revealing than static filings. As David Shapiro, Chief Executive Officer of B2i Digital, Inc., noted, “Reading company filings is a great cure for insomnia, but if you want to stay awake and hear it directly from management, these conferences are the best way to get a real feel for the company. My favorite part is the Q&A and hearing how they handle the impromptu questions that are really on your mind.”
Among the innovations on display, Sona Nanotech is developing a photothermal cancer therapy built on gold nanorods, while Raphael Pharmaceutical focuses on cannabinoid-based formulations for rheumatoid arthritis, chronic lung inflammation, and autoimmune disease. Amplia Therapeutics is advancing a pipeline of Focal Adhesion Kinase inhibitors for cancer and fibrosis, and Adaptin Bio is working on precision drug delivery technologies aimed at target tissues, including behind the blood-brain barrier. Acurx Pharmaceuticals is developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens, addressing a critical unmet need in infectious disease. CytoDyn is studying a humanized monoclonal antibody in solid-tumor oncology, and 4DMedical offers FDA-cleared four-dimensional respiratory imaging, which could improve diagnosis and monitoring of lung conditions.
The forum’s global reach is underscored by the participation of companies listed on exchanges such as the ASX and OTC Markets, reflecting the international nature of life sciences investment. Virtual Investor Conferences, an OTC Markets Group Inc. property, regularly features public companies from NYSE, Nasdaq, TSX, TSXV, CSE, ASX, LSE, and OTC Markets, providing a platform for efficient investor engagement. For those interested in attending, registration is available at https://www.virtualinvestorconferences.com/wcc/eh/4814904/category/150412/september-17th-life-sciences-virtual-investor-forum?utm_source=b2i&utm_medium=marketing&utm_campaign=0917SeptLifeScienceVIC, and event details and company profiles can be found at https://b2idigital.com/sept-17-life-sciences-virtual-investor-forum.
The significance of this forum lies in its ability to connect investors with a broad spectrum of life sciences innovations at a time when capital allocation in the sector demands careful due diligence. By providing live Q&A and on-demand replays, the event lowers barriers to access and enables investors to assess management teams’ responsiveness and strategic clarity. Moreover, the diversity of presenting companies—from antibiotics targeting priority pathogens to cannabinoid therapeutics—highlights the expanding frontiers of biotech and the potential for breakthroughs across multiple disease areas. As the life sciences landscape continues to evolve, forums like this play a vital role in fostering informed investment decisions and supporting the development of novel therapies.
